Charles Schwab Investment Management Inc. Grows Stock Holdings in AxoGen, Inc. (NASDAQ:AXGN)

Charles Schwab Investment Management Inc. increased its holdings in AxoGen, Inc. (NASDAQ:AXGN - Free Report) by 14.5% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 416,610 shares of the medical equipment provider's stock after acquiring an additional 52,846 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.95% of AxoGen worth $6,866,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its position in AxoGen by 3.2% in the third quarter. Geode Capital Management LLC now owns 1,010,508 shares of the medical equipment provider's stock valued at $14,170,000 after purchasing an additional 31,612 shares during the period. FMR LLC grew its holdings in shares of AxoGen by 743.1% in the third quarter. FMR LLC now owns 178,957 shares of the medical equipment provider's stock valued at $2,509,000 after purchasing an additional 157,730 shares in the last quarter. Barclays PLC increased its stake in AxoGen by 119.3% during the 3rd quarter. Barclays PLC now owns 72,036 shares of the medical equipment provider's stock worth $1,010,000 after buying an additional 39,182 shares during the period. State Street Corp lifted its holdings in AxoGen by 11.9% during the 3rd quarter. State Street Corp now owns 896,674 shares of the medical equipment provider's stock worth $12,571,000 after buying an additional 95,051 shares in the last quarter. Finally, Principal Financial Group Inc. purchased a new position in AxoGen in the 3rd quarter valued at approximately $207,000. Institutional investors and hedge funds own 80.29% of the company's stock.

Remove Ads

Analyst Ratings Changes

AXGN has been the topic of several analyst reports. Canaccord Genuity Group increased their price objective on AxoGen from $22.00 to $26.00 and gave the company a "buy" rating in a research note on Wednesday, February 26th. Cantor Fitzgerald restated an "overweight" rating and set a $24.00 price target on shares of AxoGen in a report on Wednesday, March 5th. Finally, Lake Street Capital started coverage on AxoGen in a research report on Monday, March 17th. They set a "buy" rating and a $30.00 price objective for the company. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $22.60.

Insiders Place Their Bets

In other AxoGen news, insider Erick Wayne Devinney sold 15,111 shares of the firm's stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $17.50, for a total transaction of $264,442.50. Following the transaction, the insider now owns 217,762 shares of the company's stock, valued at approximately $3,810,835. This trade represents a 6.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Amy Mcbride Wendell sold 5,000 shares of the business's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $20.02, for a total value of $100,100.00. Following the completion of the sale, the director now directly owns 97,899 shares of the company's stock, valued at $1,959,937.98. The trade was a 4.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.00% of the stock is owned by corporate insiders.

AxoGen Stock Down 3.3 %

Shares of NASDAQ AXGN traded down $0.63 during midday trading on Friday, hitting $18.36. 423,717 shares of the company's stock were exchanged, compared to its average volume of 418,337. The firm's fifty day simple moving average is $18.27 and its 200-day simple moving average is $15.79. The company has a market cap of $814.16 million, a PE ratio of -57.38 and a beta of 1.02. AxoGen, Inc. has a twelve month low of $5.55 and a twelve month high of $21.00. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.74 and a quick ratio of 2.47.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.